Mercer Global Advisors
FBLG icon

Mercer Global Advisors’s FibroBiologics FBLG Stock Holding History

Mercer Global Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-514
Closed -$51.3K – 2061
2024
Q2 		$51.3K Buy
+514
New +$98K ﹤0.01% 1909

Other funds holding FBLG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AIFAIM
American Institute for Advanced Investment Management Scottsdale, Arizona $173M AUM 25.3% 1-Year Est. Return

Mercer Global Advisors's FBLG Position: Q3 2024 in Review

Mercer Global Advisors sold out of FibroBiologics (FBLG) in Q3 2024, closing a stake of 514 shares — an estimated $51.3K sold.

Mercer Global Advisors first reported a position in FBLG in Q2 2024 and held it in 1 quarter. The position peaked at $51.3K in Q2 2024. 61 funds tracked by Wall St. Rank hold FBLG as of Q3 2024.

  • Mercer Global Advisors reported no remaining FibroBiologics position as of Q3 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 514 FibroBiologics shares in Q3 2024, an estimated $51.3K.
  • Mercer Global Advisors first reported a position in FibroBiologics in Q2 2024 and held it in 1 quarter.
  • Mercer Global Advisors's FibroBiologics position peaked at $51.3K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2024.

Based on Mercer Global Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.